Understanding the Market | LEE'S PHARM rose over 27% in the afternoon as the application for the new indication of Socazoli monoclonal antibody was approved. Institutions are focusing on the palliative care track
I'm PortAI, I can summarize articles.
LEE'S PHARM's stock price rose over 27% in the afternoon, and as of the time of writing, it has increased by 20.9%, reaching HKD 2.43, with a trading volume of HKD 44.9021 million. The company's interim results show a revenue of HKD 695 million, a year-on-year increase of 5.5%. The new indication application for Socazolimab submitted by its subsidiary has been approved. Dongxing Securities pointed out that the quality of life for cancer patients is a key focus, and LEE'S PHARM's AZ003 can effectively control cancer pain, which is expected to become an investment focus in the future
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments